CA
TEVA icon

Claro Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Claro Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,102
Closed -$201K – 504
2025
Q1 		$201K Buy
13,102
+680
+5% +$12.1K 0.03% 490
2024
Q4 		$274K Sell
12,422
-154
-1% -$2.8K 0.04% 379
2024
Q3 		$227K Buy
+12,576
New +$220K 0.03% 456
2019
Q1 		– Sell
-814
Closed -$18K – 845
2018
Q4 		$18K Buy
+814
New +$16.7K 0.01% 569

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Claro Advisors's TEVA Position: Q2 2025 in Review

Claro Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 13,102 shares — an estimated $201K sold.

Claro Advisors first reported a position in TEVA in Q4 2018 and held it in 4 quarters. The position peaked at $274K in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Claro Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Claro Advisors sold 13,102 Teva Pharmaceuticals shares in Q2 2025, an estimated $201K.
  • Claro Advisors first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Claro Advisors's Teva Pharmaceuticals position peaked at $274K in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Claro Advisors's 13F filing for Q2 2025, filed 5 Aug 2025.